108 related articles for article (PubMed ID: 24669387)
1. Etoricoxib: a French review of adverse effects.
Prescrire Int; 2014 Feb; 23(146):45. PubMed ID: 24669387
[TBL] [Abstract][Full Text] [Related]
2. Fixed drug eruption and generalised erythema following etoricoxib.
Augustine M; Sharma P; Stephen J; Jayaseelan E
Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
[No Abstract] [Full Text] [Related]
3. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
[TBL] [Abstract][Full Text] [Related]
4. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs.
Di Leo E; Aloia AM; Nettis E; Cardinale F; Foti C; Distaso M; Ferrannini A; Vacca A
Int J Immunopathol Pharmacol; 2009; 22(4):1131-4. PubMed ID: 20074479
[TBL] [Abstract][Full Text] [Related]
5. Mucosal exfoliation as a selective reaction to etoricoxib.
Patanè M; Isola S; Gangemi S; Minciullo PL
J Clin Pharm Ther; 2016 Dec; 41(6):722-724. PubMed ID: 27576781
[TBL] [Abstract][Full Text] [Related]
6. Emerging from the shadow of Vioxx.
Lindsley CW
Curr Top Med Chem; 2007; 7(7):739. PubMed ID: 17450647
[No Abstract] [Full Text] [Related]
7. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
Cimbollek S; Quiralte J; Avila R
N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
[No Abstract] [Full Text] [Related]
9. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
11. Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects.
Pagani M; Bonadonna P; Dama A; Senna GE; Vescovi PP; Antico A
Eur Ann Allergy Clin Immunol; 2010 Dec; 42(6):216-20. PubMed ID: 21287945
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
14. Etoricoxib and the treatment of ankylosing spondylitis.
Lories RJ
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1599-608. PubMed ID: 23126318
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
[TBL] [Abstract][Full Text] [Related]
16. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
[TBL] [Abstract][Full Text] [Related]
18. Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Soares J
Clin Drug Investig; 2009; 29 Suppl 2():26-8. PubMed ID: 19938885
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
Krum H; Swergold G; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
J Hypertens; 2009 Apr; 27(4):886-93. PubMed ID: 19516186
[TBL] [Abstract][Full Text] [Related]
20. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
